DUBLIN–(BUSINESS WIRE)–The “Innovations
in Stem Cells, Cellular Therapies, Diabetes Therapy, Gene Therapies,
Antiaging Research, Biomarkers, and Vaccines” report has been
added to ResearchAndMarkets.com’s offering.
The Life Science, Health & Wellness TechVision Opportunity Engine (TOE)
comprises analytical insights across various innovations.
The TOE describes disruptive technological developments across stem cell
platforms, personalized medicine, use of artificial intelligence for
Alzheimer’s disease, gene therapies, melanoma management, biomarkers,
vaccines, liver cancer management, monoclonal antibodies, and the
management of post-partum depression.
Key Topics Covered
- Celularity
- Rubius Therapeutics
- Magenta Therapeutics
- Semma Therapeutics
- Orig3n
- University of California San Francisco (UCSF)
- UCSF
- MeiraGTx
- Boston University School of Medicine
- Gero
- Epitopoietic Research Corporation
- Provention Bio
- Sage Therapeutics
- Basilea Pharmaceutica
- Exelixis
- NYU
- University of Washington
- Roslin Institute Features of chicken eggs as bioreactors
- ESCO Aster
- Agenus
- Indian Institute of Technology, Mandi
- Liverpool School of Tropical Medicine
- University of Chicago
- UroGen
- Unity Biotechnology
- Bruin Biometrics
- Teva Pharmaceutical Industries
- Key Contacts
For more information about this report visit https://www.researchandmarkets.com/research/tfgwlr/2019_innovations?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Stem
Cells, Biomarkers,
Vaccines,
Endocrinology